AB 1982 obligates holders (and new applicants) of Type 48 on‑sale general public premises licenses to make drug‑testing devices available for customers and to display a specified warning sign. The bill defines the devices and lists example controlled substances, requires that devices not be past their labeled expiration, and allows licensees to distribute devices free of charge.
The measure also bars criminal penalties for violations, shields licensees from liability for inaccurate test results, and directs the state department to publish guidance and the required signage online. The provision is time‑limited: it becomes operative July 1, 2024, and repeals January 1, 2027 — a temporary, compliance‑focused mandate that will matter to operators, compliance officers, product suppliers, and health‑and‑safety managers at licensed premises.
At a Glance
What It Does
Requires Type 48 (on‑sale general public) licensees to offer drug‑testing devices for sale at a price tied to wholesale cost, post a prescribed notice, ensure devices are unexpired, and links the department to publish implementation details online. It also exempts violations from criminal punishment and limits licensee liability for inaccurate results.
Who It Affects
Businesses holding or applying for a Type 48 license (on‑sale general public premises), vendors and distributors of drink‑spiking test kits, and the state licensing department responsible for posting guidance. Compliance officers and venue managers will have procurement, storage, signage, and staff‑training responsibilities.
Why It Matters
This creates a sector‑specific, time‑limited harm‑reduction obligation within California’s alcohol licensing regime, shifting small operational costs to licensees while explicitly removing criminal exposure and placing product‑quality obligations on sellers. The statute also establishes a model other jurisdictions could copy or study during the pilot period.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill defines “drug testing devices” broadly to include strips, stickers, straws, and similar products designed to detect controlled substances in drinks, and it names specific examples of those substances. It then requires that any existing or new Type 48 licensee offer such devices for sale to customers, with the sale price not to exceed a reasonable markup relative to wholesale cost.
Licensees may also provide devices free of charge.
AB 1982 mandates a single, prominent, on‑premises notice whose text is specified in the statute; venues must post that sign where customers will see it. The statute places an affirmative product‑quality duty on licensees to ensure any testing devices offered have not passed the manufacturer‑recommended expiration or period of use.
To reduce operators’ exposure, the bill disclaims civil liability for defective or inaccurate test results and clarifies that violations of this section are not criminal offenses.The Department is tasked with publishing a web page that links to required signage and describes the types of testing devices to be available, which will serve as the central implementation and informational resource. Finally, the law is explicitly temporary: it becomes operative July 1, 2024, and sunsets on January 1, 2027, signaling a limited pilot or transitional policy rather than a permanent licensing change.
The Five Things You Need to Know
The statute requires Type 48 licensees to offer drug‑testing devices for sale at a cost “not to exceed a reasonable amount based on the wholesale cost” of those devices.
The law prescribes exact signage text that licensees must post: “Don’t get roofied! Drink lids and drink spiking drug test kits available here. Ask a staff member for details.”, Licensees must ensure any device they offer has not exceeded its expiration date or recommended period of use as shown on the product label or manufacturer guidance.
The bill explicitly immunizes Type 48 licensees from liability for defective or inaccurate test results, and states that violating this section is not a crime.
The provision is time‑limited: it is operative July 1, 2024, and will be repealed on January 1, 2027.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Definitions—what counts as a device and which substances are in scope
This subsection sets the working definitions the rest of the statute uses. It defines “drug testing devices” by form factor (strips, stickers, straws, and similar items) and enumerates example controlled substances — including flunitrazepam, ketamine, and GHB and its chemical synonyms. Practically, the definition is broad enough to capture current consumer test kits but does not include a testing‑method standard or certification requirement.
Sale requirement for Type 48 licensees
License holders and applicants for new Type 48 licenses must offer testing devices for sale to customers. The pricing rule ties retail to wholesale via a nebulous “reasonable amount” standard rather than a fixed markup or cap, leaving room for interpretation and potential administrative guidance on acceptable retail pricing relative to cost.
Mandatory on‑premises signage
Licensees must display a single, specified notice in a prominent and conspicuous spot. The statute reproduces the exact wording, which creates a clear compliance checkpoint inspectors can verify visually. Because the text is fixed, businesses cannot substitute alternate language without deviating from the statute.
Option to provide devices free of charge
This short clause preserves licensees’ discretion to give devices away. From a compliance perspective, it means establishments that want to absorb the cost, run a safety program, or avoid transaction friction can do so without triggering the sale requirement’s pricing mechanics.
Liability protection for licensees
The statute states a licensee “shall not be held liable” for defective or inaccurate test results, explicitly covering false positives and false negatives. That language is defensive: it reduces civil‑law exposure but does not extinguish third‑party claims that might be pursued under other statutory theories or by actors outside the scope of the licensee relationship.
Product expiration and manufacturer guidance duty
Licensees must ensure any offered device is within its labeled expiration or recommended period of use. This creates an operational control: venues need a supply‑chain process, inventory checks, and staff training to verify dates and manufacturer instructions, since the statute ties compliance to product labeling rather than to laboratory validation.
Violations are noncriminal
Contrary to some licensing statutes that attach criminal penalties, this provision makes clear that breaching the section is not a crime. It narrows enforcement remedies to administrative, civil, or market mechanisms unless other laws apply, and it reduces the immediate criminal exposure of licensees and staff for failures to comply.
Department duty to publish guidance and signage
The department must post a webpage linking to the required signage and describing the types of devices that should be available. That centralizes the information flow and makes the department the de facto source for acceptable device types and compliance examples, although the statute does not specify a deadline or enforcement mechanisms tied to that posting.
Operative date and sunset
The section is explicitly temporary: it becomes operative July 1, 2024, and sunsets January 1, 2027. The finite window suggests a pilot or interim policy; it also affects procurement decisions because venues will need to weigh short‑term costs against the limited duration of the requirement.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Patrons concerned about drink‑spiking — they gain easier access to consumer test devices on licensed premises, potentially reducing exposure to certain incapacitating drugs.
- Public and event safety teams — venues that adopt device distribution can incorporate it into broader harm‑reduction strategies and communicate a visible commitment to patron safety.
- Manufacturers and distributors of consumer drink‑testing products — AB 1982 creates a predictable retail channel (licensed premises) and potential demand spike during the statute’s operative period.
- Licensees that prioritize risk management — the explicit liability shield reduces their civil exposure for inaccurate device results and clarifies one legal risk vector.
Who Bears the Cost
- Type 48 licensees — responsible for procuring devices, checking expirations, posting signage, and training staff, which creates administrative and inventorying costs.
- State licensing department — tasked with producing and maintaining the informational web page and signage resources without the statute providing funding or timelines.
- Customers — unless the licensee distributes devices free, customers will pay for devices at a price tied to wholesale cost; transaction friction and cost sensitivity may limit uptake.
- Device vendors — must supply products with clear labeling of expiration and usage periods; vendors lacking that labeling may be excluded from venue offerings.
Key Issues
The Core Tension
The central dilemma is a trade‑off between immediate harm‑reduction access and the risk of false reassurance: the bill expands availability of drink‑spiking test kits to reduce danger to patrons, but it stops short of requiring validated devices or enforcement mechanisms, while shielding venues from liability — a combination that may increase access but also the chance that patrons will rely on imperfect tests.
The bill assumes consumer drink‑testing devices are a meaningful harm‑reduction tool but does not set product performance, accuracy, or quality standards. That creates an implementation gap: venues must ensure devices are unexpired, but the statute leaves it to market actors and the department’s forthcoming web page to identify which devices are appropriate.
Without minimum sensitivity/specificity thresholds or certification, venues may offer products that provide unreliable results while relying on the statutory liability shield.
Enforcement and oversight are ambiguous. The statute removes criminal penalties but does not specify administrative sanctions, inspection protocols, or who enforces the requirement.
The department’s obligation to post guidance is helpful, but the absence of deadlines or resourcing raises practical questions. Finally, the sunset date limits long‑term investment in training or integrated safety programs, potentially discouraging comprehensive rollouts and instead encouraging minimal compliance for a temporary period.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.